MedTrace Logo

Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women With Breast Cancer

NCT03855423 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-04-19

No results posted yet for this study

Summary

Phase Ib: Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women with Breast Cancer is aimed to determine the highest, safest and tolerable dose of Tocotrienol-rich Fraction (maximal tolerated dose: MTD) that can be used in women with breast cancer.

Conditions

  • Breast Cancer Female

Interventions

DIETARY_SUPPLEMENT

Tocotrienol-rich Fraction (TRF)

TRF consists of alpha, gamma and delta tocotrienols in addition to small amount of alpha-tocopherol

Sponsors & Collaborators

  • Malaysia Palm Oil Board

    collaborator OTHER_GOV

  • Nur Aishah Mohd Taib

    lead OTHER

Principal Investigators

  • Nur Aishah Taib, MBBS · University of Malaya

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-18
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03855423 on ClinicalTrials.gov